Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Immutep ADS Representing 10 Ord Shs IMMP

Healthcare Biotechnology
Immutep Limited is an Australia-based clinical-stage biotechnology company. The Company is focused on developing Lymphocyte Activation Gene (LAG)-3 immunotherapies for cancer and autoimmune diseases. Its lead product candidate, Eftilagimod alpha (efti or IMP321), is a soluble LAG-3Ig fusion protein that is an antigen-presenting cell (APC) agonist designed to capitalize on LAG-3’s ability to... see more

Recent & Breaking News (NDAQ:IMMP)

Immutep Successfully Completes Recruitment for Phase II TACTI-002 Study of LAG-3 Therapy, Eftilagimod Alpha

GlobeNewswire November 19, 2021

Immutep Publishes AIPAC, TACTI-002 and TACTI-003 Trial Posters at SITC with Positive New Data for LAG-3 Therapy, Eftilagimod Alpha

GlobeNewswire November 15, 2021

Immutep Granted Chinese Patent for Eftilagimod Alpha, a Soluble Lag-3 Fusion Protein, in Combination with a PD-1 Pathway Inhibitor

GlobeNewswire November 15, 2021

Immutep Announces Publication of AIPAC, TACTI-002 and TACTI-003 Abstracts for SITC 2021 Annual Meeting & AIPAC Global Webcast Details

GlobeNewswire November 9, 2021

Immutep Reports Improved and Statistically Significant Survival Benefit for Three Key Patient Groups in Final Phase IIb AIPAC Study Results in Metastatic Breast Cancer

GlobeNewswire November 9, 2021

Immutep Granted Chinese Patent for Eftilagimod Alpha, a Soluble Lag-3 Protein, in Combination with a Chemotherapy Agent

GlobeNewswire November 2, 2021

Immutep Receives Positive EMA Scientific Advice for Further Clinical Development of Efti in MBC Including Phase III

GlobeNewswire October 29, 2021

Immutep Quarterly Activities Report & Appendix 4C

GlobeNewswire October 28, 2021

Immutep to Present Phase II TACTI-002 Data at SITC 2021

GlobeNewswire October 1, 2021

Immutep Receives A$3.4 million R&D Tax Incentive from French Government

GlobeNewswire September 29, 2021

Immutep to Present at Healthcare Investor Conferences

GlobeNewswire September 28, 2021

Immutep to Present Final Overall Survival Data From Phase IIb AIPAC as a Late Breaking Poster Presentation at SITC 2021

GlobeNewswire September 21, 2021

Immutep Completes Recruitment of 2nd line PD-1/PD-L1 refractory NSCLC Patients in TACTI-002

GlobeNewswire September 1, 2021

Immutep's Chinese Partner, Eoc Pharma, Expands Efti Trial Pipeline

GlobeNewswire August 31, 2021

Immutep Announces Chinese Patent Grant for LAG-3 Antagonist Antibody LAG525

GlobeNewswire August 27, 2021

Immutep Reports Dosing of First Patient for Triple Combination (efti + anti-PD-1 + chemo) in INSIGHT-003

GlobeNewswire August 5, 2021

Immutep Quarterly Activities Report

GlobeNewswire July 13, 2021

Immutep receives FDA and IRB approval in the US for Phase IIb TACTI-003 trial in HNSCC

GlobeNewswire July 6, 2021

Immutep to Evaluate Efti in Triple Combination Therapy Phase I Study with Chemotherapy and an anti-PD-1 Therapy

GlobeNewswire June 21, 2021

Immutep Completes a A$60 Million Placement to Expand its Clinical Development and Manufacturing Program into Late-Stage Settings

GlobeNewswire June 21, 2021